Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by equities researchers at Citigroup to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.
GLX has been the subject of several other research reports. Citizens Jmp raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, December 9th. ATB Cormark Capital Markets lowered Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research report on Thursday, February 5th. Five equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.
Get Our Latest Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
- REVEALED: Something Big Happening Behind White House Doors
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Read this or regret it forever
- Unlocked: Elon Musk’s Next Big IPO
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
